Received Jun 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 4 | 039A20A | IM |
Low grade B cell non-Hodgkin's lymphoma; This spontaneous case was reported by a consumer and describes the occurrence of B-CELL LYMPHOMA (Low grade B cell non-Hodgkin's lymphoma) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039A20A, 027A21A, 058E21A and 065K21A) for COVID-19 prophylaxis. Concurrent medical conditions included Gaucher's disease, Hypertension and Obesity. On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) .5 milliliter. On 08-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) dosage was changed to .5 milliliter. On 11-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) dosage was changed to .5 milliliter. On 05-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) dosage was changed to .5 milliliter. On 15-Jul-2023, after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced B-CELL LYMPHOMA (Low grade B cell non-Hodgkin's lymphoma) (seriousness criterion medically significant). At the time of the report, B-CELL LYMPHOMA (Low grade B cell non-Hodgkin's lymphoma) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use), the reporter did not provide any causality assessments. No concomitant medication was reported. Moderna COVID-19 Vaccine Dose 5 with lot AU3918E taken on 7-Nov-2023 and Dose 6 lot number 3042388 taken on 08-Oct-2024. The patient was diagnosed with low grade B cell non-Hodgkin's lymphoma in Jul-2023 after receiving the Moderna COVID-19 vaccine. She also had an incurable, lysosomal storage disorder genetic (Gaucher's) disease in which she had a Medi port that she took treatment, and an enzyme replacement therapy every other week to stay alive. She also had hypertension and was obese, all which was confirmed to be pre-existing prior to receiving the COVID-19 vaccines.; Reporter's Comments: Due to lack of biological plausibility (and long latency), the causality of the events was assessed as not related to the vaccine. The benefit -risk relationship of product is not affected by this report.
Gaucher's disease; Hypertension; Obesity